New insights on personalized cancer treatments: A report from the ESMO Congress

Expert Review of Anticancer Therapy

Volumn 11, Issue 1, 2011, Pages 21-23

  Ciardiello, Fortunato ^a   Jezdic, Svetlana ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; GEFITINIB; IPI 926; LDE 225; METMAB; MONOCLONAL ANTIBODY; PACLITAXEL; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

BASAL CELL CARCINOMA; CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CHONDROSARCOMA; CONFERENCE PAPER; DRUG FORMULATION; EDUCATION PROGRAM; HEALTH CARE PERSONNEL; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL INFORMATION; MEDICAL SOCIETY; MEDULLOBLASTOMA; ONCOLOGY; OSTEOSARCOMA; SPINDLE CELL CARCINOMA;

HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; RADIATION ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78650431570     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.212     Document Type: Conference Paper

References (16)

1. De Bono J, Logothetis C, Fizazi K et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled Phase III study. Ann. Oncol. 21(Suppl. 8), viii3 (2010) (Abstract LBA5).
2. Zhou C, Wu Y-L, Chen G et al. OPTIMAL (CTONG 0802) study comparing frst-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann. Oncol. 21(Suppl. 8), viii6 (2010) (Abstract LBA13).
3. Wu Y-L, Zhou C, Chen G et al. First biomarker analyses from a Phase III, randomized, open-label, frst-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL, CTONG 0802). Ann. Oncol. 21(Suppl. 8), viii6 (2010) (Abstract LBA14).
4. Perren T, Swart AM, Pfsterer J et al. ICON7: a Phase III randomized Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC). Ann. Oncol. 21(Suppl. 8), viii2-viii3 (2010) (Abstract LBA4).
5. Pavel M, Hainsworth JD, Baudin E et al. A randomized, double-blind, placebo trial of everolimus octreotide LAR vs placebo octreotide LAR in patients with advanced neuroendocrine tumors -controlled, multicenter Phase III (NET) (RADIANT-2). Ann. Oncol. 21(Suppl. 8), viii4 (2010) (Abstract LBA8).
6. Yao JC, Shah MH, Ito T et al. A randomized, double-blind, placebo-controlled, multicenter Phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). Ann. Oncol. 21(Suppl. 8), viii4-5 (2010) (Abstract LBA9).
7. Spigel D, Ervin T, Ramlau R et al. Randomized multicenter double-blind placebo-controlled Phase II study evaluating MetMAb, an antibody to MET receptor, in combination with erlotinib, in patients with advanced non-small cell lung cancer. Ann. Oncol. 21(Suppl. 8), viii7 (2010) (Abstract LBA15).
8. Long GV, Kefford RF, Carr PJA et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Ann. Oncol. 21(Suppl. 8), viii12 (2010) (Abstract LBA27).
9. Miller VA, Hirsh V, Cadranel J et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) best supportive care (BSC) versus placebo BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or geftinib (LUX-LUNG 1). Ann. Oncol. 21(Suppl. 8), viii1 (2010) (Abstract LBA1).
10. Awada A, Bondarenko IN, Tarasova O et al. Results of the frst randomized Phase II study of cationic liposomal paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann. Oncol. 21(Suppl. 8), viii5-viii6 (2010) (Abstract LBA12).
11. Berlin J, Bendell J, Hart LL et al. Placebo-controlled study of Hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (MCRC). Ann. Oncol. 21(Suppl. 8), viii10 (2010) (Abstract LBA21).
12. Kaye SB, Fehrenbacher L, Holloway R et al. A phase 2, randomized, placebo-controlled study of Hedgehog (HH) pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd or 3rd complete remission (CR). Ann. Oncol. 21(Suppl. 8), viii11 (2010) (Abstract LBA25).
13. Rodon Ahnert J, Baselga J, Tawbi H et al. LDE225, a smoothened (SMO) antagonist: Phase I safety and pharmacologic results in patients with advanced tumors. Ann. Oncol. 21(Suppl. 8), viii164 (2010) (Abstract 502PD).
14. Rudin CM, Weiss GJ, Chang AC et al. A Phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients (pts) with advanced or metastatic solid tumors. Ann. Oncol. 21(Suppl. 8), viii164 (2010) (Abstract 501PD).
15. Kiesslich T, Wachter J, Alinger B, Ocker M, Neureiter D, Berr F. Hedgehog signaling is active in biliary tract cancer and amenable to pharmacological inhibition. Ann. Oncol. 21(Suppl. 8), viii47 (2010) (Abstract 95P).
16. Bastian L, Pfugmacher R, Berenson JR et al. First randomized trial comparing balloon kyphoplasty (BKP) to non-surgical management among cancer patients with vertebral compression fractures. Ann. Oncol. 21(Suppl. 8), viii363 (2010) (Abstract 1181O).